Universitätsklinikum Düsseldorf
Universitätsklinikum Düsseldorf
Düsseldorf, Germany35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-10-09 | NCT04929223 | |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Digestive System Diseases, Infections, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 3 | 2026-10-08 | NCT07200908 | |
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, heart disorder, heart failure, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05374291 | |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | interstitial lung disease, lung disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06806592 | |
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06962839 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Nutritional and Metabolic Diseases, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, type 2 diabetes mellitus, vascular disorder | Recruiting | Phase 3 | 2026-09-30 | NCT07064473 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | Extrapulmonary Neuroendocrine Cancer (epNEC) | Recruiting | Phase 3 | 2026-09-29 | NCT07544654 | |
| A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy | Muscle-invasive Bladder Cancer | Active, not recruiting | Phase 3 | 2026-09-28 | NCT04660344 | |
| Medtronic Cardiac Surgery PMCF Registry | cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not stated | 2026-09-25 | NCT04073420 | |
| A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Not stated | 2026-09-15 | NCT06780150 | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | large B-cell lymphoma | Active, not recruiting | Phase 3 | 2026-09-11 | NCT06047080 | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05271409 | |
| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum | Skin Ulcer, Skin and Connective Tissue Diseases, pyoderma, pyoderma gangrenosum, skin disorder, skin vascular disease | Recruiting | Phase 3 | 2026-09-02 | NCT06624670 | |
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 4 | 2026-09-01 | NCT07788586 | |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-08-17 | NCT06216158 | |
| A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-08-05 | NCT05676203 | |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Disease Attributes, Hemic and Lymphatic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-17 | NCT02598661 | |
| Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT06501625 | |
| Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Not stated | 2026-04-23 | NCT07264426 | |
| Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients | Hemic and Lymphatic Diseases, anemia, hematologic disorder, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Active, not recruiting | Not stated | 2026-04-14 | NCT05582902 | |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-03-25 | NCT06455202 | |
| Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-01-05 | NCT01252485 | |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) | Disease Attributes, Disease Progression, Neurologic Manifestations, Ocular Motility Disorders, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, progressive supranuclear palsy, tauopathy | Active, not recruiting | Phase 2 | 2025-10-15 | NCT06355531 |